Oxford Nanopore Technologies ONT.L
United KingdomHealthcare · BiotechnologyLondon Stock Exchange · GBP
2.01 GBP (−8.8%)
11 analysts
Trading 2120.30 €Open account ↗
Trade Republic1.00 €Open account ↗
XTB1.00 €affiliateOpen account ↗XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Trade Republic1.00 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Oxford Nanopore Technologies develops and commercializes portable real-time DNA/RNA sequencing devices, selling both the instruments and the associated high-margin consumables.
Listed on London Stock Exchange · Symbol ONT.L · LON: ONT · Currency GBP
Key points
from its scores- ✕Little or no dividend0.5
- ✕Demanding valuation0.8
- ✕Little competitive advantage3.0
AI analysis
bottom line, main risk, context and newsHold in the portfolio only for investors with high risk tolerance and a long-term horizon; it is not a stock for conservative profiles given its lack of profitability and demanding valuation.
Oxford Nanopore is a growth-stage biotechnology company with a very high gross margin (62.81%) and 10.50% revenue growth, but it continues to burn cash intensively (operating margin of -43.45%) and its valuation is extremely demanding (FCF yield of -2.30%), making it a high-risk, high-potential bet.
The main risk is sustained cash burn (operating margin of -43.45%) which, combined with a very demanding valuation, leaves little room for error if revenue growth decelerates or adoption of its technology fails to reach the expected scale.
Context and risks
Oxford Nanopore operates in the UK health technology sector, a country with moderate governance risk. Its business model, based on selling sequencing devices and consumables, has no material exposure to interest rates, oil, or shipping routes. The adjustment reflects only the standard regulatory and governance risk of the country of domicile.
Is Oxford Nanopore Technologies stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 169% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 5.1 | 4.1 | +23% |
| Price / sales | 9.2 | 3.4 | +169% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 2.01 GBP, −8.8% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 3.0 (sector 5.5), Growth 6.9 (sector 6.6).
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −30.5
- EV / EBITDA
- −21.7
- Price / book
- 5.1
- Price / sales
- 9.2
- Market cap
- 2.2B GBP
- Enterprise value
- 2.0B GBP
Profitability
- ROE
- −25.6%
- ROA
- −10.9%
- ROIC (approx.)
- −21.8%
- Gross margin
- 62.8%
- Operating margin
- −43.4%
- Net margin
- −51.7%
- Free cash flow
- −49.7M GBP
- FCF yield
- −2.3%
Solvency
- Total debt
- 41.8M GBP
- Net debt
- −143.0M GBP
- Cash
- 184.8M GBP
- EBITDA
- −92.4M GBP
- Net debt / EBITDA
- 1.55
- Debt / equity
- 9.86
- Current ratio
- 3.52
- Quick ratio
- 2.73
Growth
- Revenue growth
- +10.5%
- EPS (TTM)
- −0.13 GBP
- EPS (forward)
- −0.07 GBP
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 0.87
- Analyst consensus
- Buy (11)
- Target price
- 2.01 GBP
Recent news
All ONT.L news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Oxford Nanopore Technologies
Is Oxford Nanopore Technologies stock cheap or expensive?
On Price / sales, it trades 169% above the Healthcare median. Valuation score: 0.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 2.01 GBP, −8.8% versus the price. This is not investment advice.
What score does Oxford Nanopore Technologies get on MeridIAn Screener?
It scores 3.8 out of 10, rank 2,001 of 2,130 (better than 6% of the companies analysed). Its strongest category is Growth (6.9) and its weakest, Dividend (0.5). Analysis of 08/10/2026.
How much is Oxford Nanopore Technologies worth on the stock market?
Its market capitalisation is 2.2B GBP and its enterprise value, debt included, is 2.0B GBP.
How much debt does Oxford Nanopore Technologies have?
It has more cash than debt: net cash of 143.0M GBP.
Does Oxford Nanopore Technologies pay a dividend?
It pays no dividend, or almost none.
How has Oxford Nanopore Technologies stock performed over the last year?
It has risen 50.3% over the last year, excluding dividends. Over the last 52 weeks it has traded between 0.00 and 2.39 GBP. Past performance does not guarantee future results.
What do analysts think of Oxford Nanopore Technologies?
11 analysts cover it; their average recommendation is “Buy” and their average target is 2.01 GBP (−8.8% versus the price). It is an estimate, not market data.